$XBI $123.68 +1.0%
Covid Updates
$NVAX -3.4% Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe source
$MBRX +2.6% Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 source
$IFRX +14.5% 10-2021-InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19 source
$ENTA +1.5% ENANTA PHARMACEUTICALS PRESENTS NEW DATA FOR EDP-235, ITS LEAD ORAL PROTEASE INHIBITOR DESIGNED FOR THE TREATMENT OF COVID-19, AT THE ISIRV–WHO VIRTUAL CONFERENCE 2021 source
Pipeline Updates
$AKRO 0.0% Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH source
$VYNE -2.6% VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis source
$IBRX +2.7% ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease source
$SANA -1.5% Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs source
$MGTX +2.6% MeiraGTx Announces the Presentation of Two Novel Inherited Retinal Disease (IRD) Programs and Riboswitch Gene Regulation Platform at the European Society of Gene and Cell Therapy (ESGCT) 2021 Annual Congress source
$AVDL +0.1% Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021 source
$DRNA +0.4% Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3) source
$PSTV +2.9% PLUS THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR 186RNL FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES source
$ASMB +1.3% Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection source
$AVRO +1.8% AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1 source
$CMPS +6.8% COMPASS Pathways is granted new US patent for crystalline psilocybin source
$AVIR -66% Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting source
$GRTX -69.6% Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis source
$PFE +1.9% Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress source
$SAGE -8.6% Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022 source
Posted by JM
Comments